- CA$32.65m
- CA$33.45m
- 42
- 64
- 26
- 40
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.29 | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
VVT Med Inc., formerly DXI Capital Corp., is a Canada-based company. The Company develops, manufactures, and commercializes invasive, non-thermal, and non-tumescent solutions for the treatment of varicose veins. The Company’s products offer several key competitive advantages over traditional alternatives, including faster treatment times, reduced pain without the need for anesthesia, and quicker recovery and results.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- August 16th, 2005
- Public Since
- July 17th, 2001
- No. of Employees
- 10
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
TSX Venture Exchange- Shares in Issue
- 66,640,102
- Address
- Suite 404; 999 Canada Pl, VANCOUVER, V6C 3E2
- Web
- Phone
- +1 6046385050
- Auditors
- Davidson & Co LLP
Similar to VVTM
Aurora Spine
TSX Venture Exchange
CardioComm Solutions
TSX Venture Exchange
Cheelcare
TSX Venture Exchange
Conavi Medical
TSX Venture Exchange
Covalon Technologies
TSX Venture Exchange
FAQ
As of Today at 24:03 UTC, shares in VVT Med are trading at CA$0.49. This share price information is delayed by 15 minutes.
Shares in VVT Med last closed at CA$0.49 and the price had moved by -34.42% over the past 365 days. In terms of relative price strength the VVT Med share price has underperformed the Toronto Stock Exchange 300 Composite Index by -47.29% over the past year.
There is no consensus recommendation for this security.
Find out moreVVT Med does not currently pay a dividend.
VVT Med does not currently pay a dividend.
VVT Med does not currently pay a dividend.
To buy shares in VVT Med you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.49, shares in VVT Med had a market capitalisation of CA$32.65m.
Here are the trading details for VVT Med:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: VVTM
Based on an overall assessment of its quality, value and momentum VVT Med is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like VVT Med. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -39.38%.
As of the last closing price of CA$0.49, shares in VVT Med were trading -81.82% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The VVT Med PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.49.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
VVT Med's management team is headed by:
- Simon Raven - PRE
- David Matheson - CFO
- Ronnie Bozzer - IND
- A. Ross Gorrell - IND
- Robert Hodgkinson - IND